News round-up for 21-25 July by DDW Senior Digital Content Editor Diana Turner.

Following the recent news that the FDA rejected Ultragenyx Pharmaceutical’s gene therapy due to manufacturing concerns, manufacturing has dominated the headlines this week, particularly significant investment in facilities in the US, and new guidelines to speed up CGT production in the UK.

The top stories:

Consortium tackles the challenge of scaling CGT manufacturing

Cellular Origins, the Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have formed a consortium to deliver a fully automated, scalable cell therapy manufacturing platform.

Read more…

AstraZeneca invests $50b in US, plans new chronic disease centre

AstraZeneca will invest $50 billion in the United States by 2030, following similar announcements by other big pharma companies.

Read more…

Biogen commits $2b to modernise US manufacturing facility

Biogen has announced that it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Read more…

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.

Read more…